Market intelligence, clinical progress, and high-purity reagents for sphingosine-1-phosphate receptor 4 immunomodulation and lymphocyte trafficking research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for S1PR4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | S1PR4 Recombinant Protein (Membrane Prep). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. | View S1PR4 Products |
| Gene Delivery | S1PR4 Lentivirus Premade Particles (full-length human ORF, NM_005887, puromycin resistance, titer >1×10^8 TU/mL) and Promise-ORF Clone (Gateway compatible, CMV promoter). Both sequence verified. | View S1PR4 Products |
| Benchmark Antibody | Anti-S1PR4 Biosimilar, recombinant positive control for assay baseline. | View S1PR4 Products |
| Validator | S1PR4 siRNA Set (3 unique sequences targeting distinct exons) for specific knockdown and pathway validation. | View S1PR4 Products |
| Related Target: S1PR1 | S1PR1 (EDG1). Dominant S1P receptor on T-cells; essential for selectivity counter-screening to avoid cardiac toxicity. | View S1PR1 Products |
| Related Target: S1PR5 | S1PR5 (EDG8). Co-expressed on lymphocytes and NK cells; distinct desensitization kinetics require parallel profiling. | View S1PR5 Products |
| Related Enzyme: SPHK1 | Sphingosine Kinase 1. Upstream S1P producer; druggable node controlling ligand availability for S1PR4 signaling. | View SPHK1 Products |
Critical Assay Requirements
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity vs. S1PR1/S1PR5 (Orthosteric pocket homology) | Human S1PR4 Lentivirus with IRES-GFP tracer; parallel S1PR1/S1PR5 stable cell lines available for orthogonal screening. |
| Native Conformation & Glycosylation | Full-length ORF expressed in HEK293T preserves native N-glycosylation sites (Asn3, Asn18); critical for ligand binding. Lentivirus particles ensure proper membrane protein folding. |
| Functional Knockdown Specificity | Three unique siRNA sequences targeting distinct exons; scramble control included to exclude off-target S1PR1/5 effects. |
| Constitutive vs. Ligand-Dependent Activity | High-titer viral prep enables stable polyclonal lines with homogeneous surface expression (verified by anti-HA/Flag flow cytometry). |
| Lack of Controls | Clinical Benchmark Antibodies (biosimilars) included for positive control. |
| False Positives | Validated siRNA and comprehensive lentivirus panels for all S1P receptors (S1PR1-5) to ensure strict selectivity screening. |
Live S1PR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Lymphocyte Trafficking Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for S1PR4-targeted therapeutics is intensifying, with major players shifting focus from pan-S1P modulation (e.g., fingolimod analogs) to subtype-selective strategies. Unlike S1PR1, which dominates peripheral lymphocyte trafficking and carries cardiovascular risks such as bradycardia, S1PR4 exhibits restricted expression to lymphoid tissues and specific leukocyte subsets, offering a refined immunological profile. The next wave of R&D targets S1PR4 as a biomarker for lymphoid malignancies, a checkpoint for B-cell differentiation, and a modulator of the tumor microenvironment (TME). Highly selective S1PR4 antagonists are expected to enter combination trials with PD-1/PD-L1 inhibitors. As first-generation non-selective therapies mature, selective S1PR4 modulation provides an avenue for effective immunomodulation without off-target bradycardia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Pharma Innovators, Novartis, Arena/Beacon | Autoimmune diseases (Lupus, MS), Graft-vs-Host Disease | Calcium Flux & Beta-arrestin assays in S1PR4-stable cell lines (Lentivirus-based) |
| Small Molecule Antagonist | Emerging Biotechs, Celgene/BMS | Solid Tumors (TME), Lymphoid Cancers (CLL, NHL) | Selectivity assay; competition binding assays using membrane fractions from high-expression lentivirus lines |
| Functional Antagonists | Early Academic/BI startups | Lymphoid Cancers (CLL, NHL), Inflammation | Pathway validation via S1PR4-specific siRNA to confirm on-target vs. S1PR1/3 effects |
| S1P Lyase Inhibitors (Upstream) | Genzyme/Sanofi, Merck KGaA | Inflammatory Bowel Disease | Pathway validation via S1PR4-specific siRNA to confirm on-target vs. S1PR1/3 effects |
| Monoclonal Antibodies | Discovery Stage | Inflammation | Epitope binding assays using sequence-verified native expression (Lentivirus) |
Key Mutation & Genetic Variant
Based on public databases, a variant is documented in dbSNP: rs3746072 (UniProt O95977 VAR_022066), which may impact protein function. This highlights the importance of sequence-verified reagents for accurate research.
Conclusion
S1PR4 represents a high-value target for next-generation immunomodulation. TarMart provides a comprehensive suite of reagents—from lentivirus particles to validated siRNA—enabling researchers to overcome selectivity and conformational challenges inherent to GPCR drug discovery.